

SRF 78898

UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK



In re

Chapter 11

ACORDA THERAPEUTICS, INC., *et al.*,¹

Case No. 24-22284 (DSJ)

Debtors.

Jointly Administered

Re: Docket Nos. 35 & 109

**NOTICE TO CONTRACT PARTIES TO POTENTIALLY
ASSUMED EXECUTORY CONTRACTS**

**YOU ARE RECEIVING THIS NOTICE BECAUSE YOU
OR ONE OF YOUR AFFILIATES IS A COUNTERPARTY
TO AN EXECUTORY CONTRACT WITH
THE DEBTORS AS SET FORTH ON EXHIBIT A ATTACHED HERETO.**

PLEASE TAKE NOTICE that on April 29, 2024, the United States Bankruptcy Court for the Southern District of New York (the “Court”) entered the *Order (A) Authorizing and Approving Bidding Procedures and Stalking Horse Bid Protections, (B) Scheduling an Auction and a Sale Hearing, (C) Approving the Form and Manner of Notice Thereof (D) Establishing Notice and Procedures for the Assumption and Assignment of Certain Executory Contracts, and (E) Granting Related Relief* [Docket No. 109] (the “**Bidding Procedures Order**”),² authorizing the Debtors to conduct an auction (the “**Auction**”) to select the party to purchase the Acquired Assets. Any Auction will be governed by the bidding procedures approved pursuant to the Bidding Procedures Order (attached to the Bidding Procedures Order as Exhibit 1, the “**Bidding Procedures**”).

PLEASE TAKE FURTHER NOTICE that, pursuant to the Bidding Procedures and the terms of any Successful Bid, the Debtors may assume and assign to the Successful Bidder the contract or agreement listed on Exhibit A (the “**Cure Notice**”) to which you are a counterparty, upon approval of the Sale. The Debtors have conducted a review of their books and records and have determined that the cure cost for unpaid monetary

¹ The Debtors in these chapter 11 cases, along with the last four (4) digits of each Debtor’s federal tax identification number, are: Acorda Therapeutics, Inc. (1168), Civitas Therapeutics, Inc. (2814), Biotie Therapies, LLC (2149), Biotie Therapies AG (N/A), Neuronex, Inc. (5094), and Acorda Therapeutics Limited (N/A). For the purposes of these chapter 11 cases, the address for the Debtors is: 2 Blue Hill Plaza, 3rd Floor, Pearl River, New York 10965.

² Capitalized terms used but not otherwise defined herein have the meanings ascribed to them in the Bidding Procedures or the Bidding Procedures Order, as applicable.

obligations under such Assigned Contracts is as set forth on **Exhibit A** attached hereto (the “Cure Costs”).

PLEASE TAKE FURTHER NOTICE that if you disagree with the proposed Cure Costs, object to a proposed assignment to the Successful Bidder of any Assigned Contract, or object to the ability of the Successful Bidder to provide adequate assurance of future performance with respect to any Assigned Contract, your objection must: (i) be in writing; (ii) comply with the applicable provisions of the Bankruptcy Code, Bankruptcy Rules, Local Bankruptcy Rules, and any order governing the administration of these Chapter 11 Cases; (iii) state with specificity the nature of the objection and, if the objection pertains to the proposed Cure Costs, state the correct cure cost alleged to be owed to the objecting counterparty to any Assigned Contract, together with any applicable and appropriate documentation in support thereof; and (iv) be filed with the Court and served and **actually received no later than May 20, 2024 at 4:00 p.m. (ET)** (the “**Contract Objection Deadline**”) by the Court and the following parties: (i) proposed counsel to the Debtors, Baker & McKenzie LLP (Attn: John R. Dodd (john.dodd@bakermckenzie.com), 1111 Brickell Avenue, 10th Floor, Miami, Florida 33131 and Blaire Cahn (blaire.cahn@bakermckenzie.com), 452 Fifth Avenue, New York, New York 10018); (ii) counsel to the Stalking Horse Bidder, Freshfields Bruckhaus Deringer US LP (Attn: Scott D. Talmadge (scott.talmadge@freshfields.com) and Ali Muffenbier (ali.muffenbier@freshfields.com), 3 World Trade Center, 175 Greenwich Street, New York, New York 10007); (iii) counsel for the U.S. Trustee (Attn: Tara Tiantian (Tara.Tiantian@usdoj.gov), Brian Masumoto (Brian.Masumoto@usdoj.gov), and Rachael E. Siegel (Rachael.E.Siegel@usdoj.gov), Alexander Hamilton Custom House, One Bowling Green, Suite 534, New York, New York 10004); (iv) counsel to the Ad Hoc Noteholder Group and DIP Lenders, King & Spalding LLP (Attn: Matthew Warren (mwarren@kslaw.com) and Lindsey Henrikson (lhenrikson@kslaw.com), 110 N Wacker Drive, Suite 3800, Chicago, Illinois 60606); (v) counsel to the DIP Administrative Agent, King & Spalding LLP (Attn: Geoffrey King (gking@kslaw.com), 110 N Wacker Drive, Suite 3800, Chicago, IL 60606); (vi) proposed counsel to the Creditors’ Committee, McDermott Will & Emery LLP (Attn: Darren Azman (dazman@mwe.com), Kristin K. Going (kgoing@mwe.com), and Stacy Lutkus (salutkus@mwe.com), One Vanderbilt Avenue, New York, NY 10017); and (vii) any other party that has filed a notice of appearance in these Chapter 11 Cases.

PLEASE TAKE FURTHER NOTICE that if no objection to: (i) the Cure Costs, (ii) the proposed assignment and assumption of any Assigned Contract, or (iii) adequate assurance of the Successful Bidder’s ability to perform is filed by the Contract Objection Deadline, then (a) you will be deemed to have stipulated that the Cure Cost as determined by the Debtors is correct, (b) you will be forever barred, estopped, and enjoined from asserting any additional cure cost under the proposed Assigned Contract, and (c) you will be forever barred, estopped, and enjoined from objecting to such proposed assignment to the Successful Bidder on the grounds that the Successful Bidder has not provided adequate assurance of future performance as of the closing date of the Sale.

PLEASE TAKE FURTHER NOTICE that any objection to the proposed assumption and assignment of an Assigned Contract or related Cure Costs in connection

with the Successful Bid that otherwise complies with these procedures yet remains unresolved as of the commencement of the Sale Hearing, shall be heard at a later date as may be fixed by the Court.

PLEASE THAT FURTHER NOTICE that, notwithstanding anything herein, the mere listing of any Assigned Contract on the Cure Notice does not require or guarantee that such Assigned Contract will be assumed by the Debtors at any time or assumed and assigned, and all rights of the Debtors and the Successful Bidder with respect to such executory contracts are reserved. Moreover, the Debtors explicitly reserves their rights, in their reasonable discretion, to seek to reject or assume each Assigned Contract pursuant to section 365(a) of the Bankruptcy Code and in accordance with the procedures allowing the Debtors and/or the Successful Bidder, as applicable, to designate any Assigned Contract as either rejected or assumed on a post-closing basis.

PLEASE TAKE FURTHER NOTICE that, nothing herein: (i) alters in any way the prepetition nature of the Assigned Contracts or the validity, priority, or amount of any claims of a counterparty to any Assigned Contract against the Debtors that may arise under such Assigned Contract, (ii) creates a postpetition contract or agreement, or (iii) elevates to administrative expense priority any claims of a counterparty to any Assigned Contract against the Debtors that may arise under such Assigned Contract.

PLEASE TAKE FURTHER NOTICE that you may obtain additional information concerning the above-captioned Chapter 11 Cases at the website maintained in these Chapter 11 Cases at <https://cases.ra.kroll.com/Acorda>.

PLEASE TAKE FURTHER NOTICE that questions regarding any proposed assumption and assignment of an Assigned Contract or related Cure Costs in connection with the Successful Bid may be directed to proposed counsel to the Debtors, Baker & McKenzie LLP via e-mail at john.dodd@bakermckenzie.com and blaire.cahn@bakermckenzie.com, and proposed counsel to the Creditors' Committee, McDermott Will & Emery LLP, via e-mail at dazman@mwe.com, kgoing@mwe.com, and salutkus@mwe.com.

[Remainder of page intentionally left blank]

Dated: May 1, 2024

/s/ John R. Dodd

John R. Dodd (admitted *pro hac vice*)
BAKER & McKENZIE LLP
1111 Brickell Avenue, 10th Floor
Miami, FL 33131
Telephone: 305-789-8900
Facsimile: 305-789-8953
Email: john.dodd@bakermckenzie.com

and

Blaire Cahn
BAKER & McKENZIE LLP
452 Fifth Avenue
New York, NY 10018
Telephone: 212-626-4100
Facsimile: 212-310-1600
Email: blaire.cahn@bakermckenzie.com

*Proposed Counsel for the Debtors
and Debtors-in-Possession*

Exhibit A

Cure Notice

No.	Contract	Counter Party(s)	Cure Amount (\$)
1.	Pre-Launch Agreement, dated as of December 15, 2021, by and between Acorda Therapeutics, Inc. and RIS RX.	RIS RX	-
2.	First Amendment to the Master Patient Support Hub Services Agreement, dated as of September 1, 2022, by and between Acorda Therapeutics, Inc. and RIS RX.	RIS RX	-
3.	Master Patient Support Hub Services Agreement, dated as of February 15, 2022, by and between Acorda Therapeutics, Inc. and RIS RX	RIS RX	\$54,780.50
4.	First Amendment to Adverse Event and Product Complaint Reporting Agreement, dated as of August 30, 2022, by and between Acorda Therapeutics, Inc. and SterlingRX, Inc.	SterlingRX	-
5.	First Amendment to the Master Direct Product Purchase and Dispensing Agreement, dated as of September 1, 2022, by and between Acorda Therapeutics, Inc. and SterlingRX, Inc.	SterlingRX	-
6.	Adverse Event and Product Complaint Reporting Agreement, dated as of February 15, 2022, by and between Acorda Therapeutics, Inc. and SterlingRX, Inc.	SterlingRX	-
7.	Master Direct Product Purchase and Dispensing Agreement, dated as of February 15, 2022, by and between Acorda Therapeutics, Inc. and SterlingRX, Inc.	SterlingRX	\$25,285.11

No.	Contract	Counter Party(s)	Cure Amount (\$)
8.	Second Amendment to the Master Patient Support Hub Services Agreement, dated as of November 18, 2022, by and between RIS Rx and Acorda Therapeutics, Inc.	RIS RX	-
9.	Third Amendment to the Master Patient Support Hub Services Agreement, dated as of March 8, 2023, by and between RIS Rx and Acorda Therapeutics, Inc.	RIS RX	-
10.	Fourth Amendment to the Master Direct Product Purchase and Dispensing Agreement, dated as of February 15, 2022, by and between SterlingRx, Inc. and Acorda Therapeutics, Inc.	SterlingRX	-
11.	Fourth Amendment to the Pharmacy Services Agreement, dated as of February 15, 2022, by and between SterlingRx, Inc. and Acorda Therapeutics, Inc.	SterlingRX	-
12.	Project Addendum #1 to the Master Market Access Service Agreement, dated as of July 19, 2018, by and between Acorda Therapeutics, Inc. and Covance Specialty Pharmacy LLC	Covance Specialty Pharmacy LLC	-
13.	McKesson Corporation Core Distribution Agreement, dated as of October 8, 2007, by and between Acorda Therapeutics, Inc. and the McKesson Corporation	McKesson Corporation	-
14.	Master Consulting Agreement, dated October 19, 2021, by and between Acorda Therapeutics Inc. and Dennis Brodsky	Dennis Brodsky	-
15.	Master Consulting Agreement, dated December 31, 2023, by and between Acorda	Alex Bonacum	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Therapeutics, Inc. and Alex Bonacum		
16.	Master Consulting Agreement, dated. April 24, 2017, by and between Acorda Therapeutics Inc. and Pharmacovigilance Physician Services LLC	Pharmacovigilance Physician Services LLC	-
17.	Master Consulting Agreement, dated as of November 13, 2020, by and between Acorda Therapeutics, Inc. and Opus Regulatory, Inc.	Opus Regulatory, Inc.	-
18.	Master Consulting Agreement, dated January 10, 2023, by and between Acorda Therapeutics, Inc. and Alex Bonacum	Alex Bonacum	-
19.	Master Consulting Agreement, dated as of February 15, 2024, by and between Acorda Therapeutics, Inc. and Gilani, LLC	Gilani LLC	\$6,000.00
20.	Schedule #1 under the Master Consulting Agreement, dated as of March 1, 2024, by and between Acorda Therapeutics, Inc. and Scientific Research Partners, LLC	Scientific Research Partners, LLC	-
21.	Master Consulting Agreement, dated as of January 8, 2024, by and between Acorda Therapeutics, Inc. and Manfred Fischer Consulting	Scientific Research Partners, LLC	-
22.	Master Consulting Agreement, dated as of March 1, 2024, by and between Acorda Therapeutics, Inc. and Scientific Research Partners, LLC	Scientific Research Partners, LLC	-
23.	Master Consulting Agreement, dated as of January 1, 2024, by and between Acorda Therapeutics, Inc. and SA Global Solutions, LLC.	SA Global Solutions, LLC	-
24.	Bill of Materials Form, dated as of January 30, 2023, by and	Sharp Corporation	\$8,825.00

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Sharp Corporation and Acorda Therapeutics, Inc.		
25.	Bill of Materials Form, dated as of March 3, 2022, by and between Sharp Corporation and Acorda Therapeutics, Inc.	Sharp Corporation	-
26.	Bill of Materials Form, dated as of August 14, 2023, by and between Sharp Corporation and Acorda Therapeutics, Inc.	Sharp Corporation	-
27.	Documents MBR-0839, MBR-0840, MBR-0982, MBR-1316, MBR-1317 dated as of January 4, 2024, by and between Catalent Pharma Solutions and Acorda Therapeutics, Inc.	Catalent Pharma Solutions	-
28.	Documents MBR-0839, MBR-0840, MBR-0982, MBR-1303, MBR-1304 dated as of January 4, 2024, by and between Catalent Pharma Solutions and Acorda Therapeutics, Inc.	Catalent Pharma Solutions	-
29.	Bill of Materials Form, dated as of August 31, 2023, by and between Sharp Corporation and Acorda Therapeutics, Inc.	Sharp Corporation	-
30.	Packaging Work Order – Bill of Materials, dated as of April 13, 2023, by and between Patheon Inc. and Acorda Therapeutics, Inc.	Patheon Inc.	-
31.	Processing Master – Cover Page and Related Documents, dated as of September 29, 2023, by and between Patheon Inc. and Acorda Therapeutics, Inc.	Patheon Inc.	-
32.	Main Agreement, dated December 16, 2014, by and between Acorda Therapeutics, Inc. and NDA Group AB	NDA Group AB	\$18,975.00
33.	Supply Agreement dated as of June 30, 2009 between Acorda Therapeutics, Inc and Biogen IDEC International GMBH	Biogen IDEC International GMBH	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
34.	Collaboration and License Agreement dated as of June 30, 2009, by and between Acorda Therapeutics, Inc. and Biogen IDEC International GmbH	Biogen IDEC International GMBH	-
35.	Addendum #1 to the Collaboration and License Agreement and Supply Agreement, dated as of May 21, 2010, by and between Acorda Therapeutics, Inc. and Biogen Idec International GmbH	Biogen IDEC International GMBH	-
36.	Addendum #2 to the Collaboration and License Agreement, dated as of March 29, 2012, by and between Acorda Therapeutics, Inc. and Biogen Idec International GmbH	Biogen IDEC International GMBH	-
37.	Addendum #3 to Collaboration and License Agreement and to Supply Agreement, dated as of February 14, 2013, by and between Acorda Therapeutics, Inc. and Biogen Idec International GmbH	Biogen IDEC International GMBH	-
38.	Addendum #4 to the Collaboration and License Agreement, dated as of October 28, 2012, by and between Acorda Therapeutics, Inc. and Biogen Idec International GmbH	Biogen IDEC International GMBH	-
39.	Amended and Restated Addendum #2 to the Supply Agreement, dated as of June 6, 2016, by and between Acorda Therapeutics, Inc. and Biogen Idec International GmbH	Biogen IDEC International GMBH	-
40.	Amendment #1 to Addendum #1 to the Collaboration and License Agreement and Supply Agreement, dated as of May 16, 2011, by and between	Biogen IDEC International GMBH	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Acorda Therapeutics, Inc. and Biogen Idec International GmbH		
41.	Amendment #1 to Manufacturing Services Agreement, dated as of August 29, 2011, by and between Acorda Therapeutics, Inc. and Patheon Inc.	Patheon Inc.	-
42.	Quality Agreement, dated as of July 20, 2021, by and between Biogen International GmbH and Alkermes Pharma Ireland Limited	Biogen International GmbH	-
43.	Addendum #2 to the Supply Agreement, dated as of August 28, 2010, by and between Acorda Therapeutics, Inc. and Biogen Idec International GmbH	Biogen IDEC International GMBH	-
44.	Fampridine Safety Data Exchange Agreement, dated as of May 24, 2023, by and between Acorda Therapeutics, Inc. and Biogen International GmbH	Biogen International GMBH	-
45.	Manufacturing Services Agreement, dated as of December 31, 2022, by and between Acorda Therapeutics, Inc. and Catalent Massachusetts LLC	Catalent Massachusetts LLC	\$1,872,711.06
46.	Asset Purchase and License Agreement, dated as of December 27, 2010, by and between Corregidor Therapeutics, Inc. and Alkermes, Inc.	Alkermes, Inc.	\$284,509.55
47.	First Amendment to Manufacturing Services Agreement, dated as of March 6, 2023, by and between Acorda Therapeutics, Inc. and Catalent Massachusetts LLC	Catalent Massachusetts LLC	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
48.	Quality Agreement, dated as of May 6, 2021, by and between Acorda Therapeutics, Inc. and Catalent Massachusetts LLC	Catalent Massachusetts LLC	-
49.	Amendment to Asset Purchase and License Agreement, dated as of December 9, 2011, by and between Civitas Therapeutics, Inc. and Alkermes, Inc.	Alkermes, Inc.	-
50.	Second Amendment to Asset Purchase and License Agreement, dated as of December 19, 2014, by and between Civitas Therapeutics, Inc. and Alkermes, Inc.	Alkermes, Inc.	-
51.	Feasibility Study Agreement, dated December 26, 2014, by and between Acorda Therapeutics, Inc. and Metrics, Inc.	Metrics, Inc.	-
52.	Amendment #1 to the Feasibility Study Agreement, dated March 12, 2015, by and between Acorda Therapeutics, Inc. and Metrics, Inc.	Metrics, Inc.	-
53.	Amendment #1 to Statement of Work #1, dated March 12, 2015, by and between Acorda Therapeutics, Inc. and Metrics, Inc.	Metrics, Inc.	-
54.	Amendment #2 to Statement of Work #1, dated September 16, 2015, by and between Acorda Therapeutics, Inc. and Metrics, Inc.	Metrics, Inc.	-
55.	Amendment #3 to Statement of Work #1, dated October 5, 2015, by and between Acorda Therapeutics, Inc. and Metrics, Inc.	Metrics, Inc.	-
56.	Master Development and Clinical Supply Agreement, dated September 15, 2015, by and between Acorda	Metrics, Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Therapeutics, Inc. and Metrics, Inc.		
57.	Patent License Agreement, dated November 1, 2016, by and between Acorda Therapeutics, Inc. and Mayne Pharma, Inc. (d/b/a Metrics Contract Services)	Mayne Pharma, Inc.	-
58.	Quote for Analytical Development, CTM Manufacture, Release Testing and Stability for Dalfampridine (4-aminopyridine) MR Tablets, 22mg, dated as of September 24, 2015, from Metrics Contract Services to Acorda Therapeutics, Inc.	Metrics, Inc.	-
59.	Statement of Work #1, dated January 5, 2015, by and between Acorda Therapeutics, Inc. and Metrics, Inc.	Metrics, Inc.	-
60.	Medicare Part D Rebate Agreement, dated as of January 1, 2021, by and between Acorda Therapeutics, Inc. and CVS Caremark Part D Services, L.L.C.	CVS Caremark Part D Services, L.L.C.	-
61.	Rebate Agreement, dated as of July 1, 2015, by and between Acorda Therapeutics, Inc. and CaremarkPCS Health, L.L.C.	CaremarkPCS Health, L.L.C.	-
62.	Medicare Part D Rebate Agreement, dated as of April 1, 2021, by and between Acorda Therapeutics, Inc. and Elixir Rx Solutions of Nevada, LLC	Elixir Rx Solutions of Nevada, LLC	-
63.	Rebate Program Agreement, dated as of July 1, 2019, by and between Acorda Therapeutics, Inc. and Ascent Health Services LLC	Ascent Health Services LLC	\$133,642.11
64.	Preferred Savings Grid Rebate Program Agreement, dated as of July 1, 2019, by and	Express Scripts, Inc.	\$58,258.70

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Acorda Therapeutics, Inc. and Express Scripts, Inc.		
65.	Medicare Part D Rebate Agreement, dated as of January 1, 2019, by and between Acorda Therapeutics, Inc. and Express Scripts Senior Care Holdings, Inc.	Express Scripts Senior Care Holdings, Inc.	-
66.	Kaiser Permanente Product Rebate and Discount Agreement, dated as of September 1, 2020, by and between Acorda Therapeutics, Inc., Kaiser Foundations Hospitals and Kaiser Foundation Health Plan, Inc.	Kaiser Foundations Hospitals Kaiser Foundation Health Plan, Inc.	\$17,048.51
67.	Rebate and Administrative Fee Agreement, dated as of January 1, 2021, by and between Acorda Therapeutics, Inc. and Navitus Health Solutions, LLC	Navitus Health Solutions, LLC	-
68.	Medicare Part D Rebate Agreement, dated as of January 1, 2016, by and between Acorda Therapeutics, Inc. and OptumRx, Inc.	OptumRx, Inc.	-
69.	Rebate Agreement, dated as of January 1, 2013, by and between Acorda Therapeutics, Inc. and OptumRx, Inc.	OptumRx, Inc.	-
70.	Commercial Rebate Agreement, dated as of January 1, 2021, by and between Acorda Therapeutics, Inc. and Zinc Health Services, LLC	Zinc Health Services, LLC	\$342,440.03
71.	Second Amendment to Supply Agreement, dated as of February 4, 2010, by and between AmerisourceBergen Drug Corporation and Acorda Therapeutics, Inc.	AmerisourceBergen Drug Corporation	-
72.	Letter re Inbrija Return Goods Policy Notice Amendment, dated as of November 22, 2019, by and among Acorda	AmerisourceBergen Drug Corporation	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Therapeutics, Inc., ASD Specialty Healthcare, Inc. and AmerisourceBergen Specialty Group, Inc.		
73.	Seventh Amendment to Distribution Services Agreement, dated as of February 1, 2019, by and between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, LLC	ASD Specialty Healthcare, LLC	-
74.	Supply Agreement, dated as of September 20, 2004, by and between Acorda Therapeutics, Inc. and AmerisourceBergen Drug Corporation	AmerisourceBergen Drug Corporation	-
75.	Amendment to Supply Agreement, dated as of May 1, 2008, by and between AmerisourceBergen Drug Corporation and Acorda Therapeutics, Inc.	AmerisourceBergen Drug Corporation	-
76.	Ninth Amendment to Distribution Services Agreement, dated as of September 6, 2019, by and between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, LLC.	ASD Specialty Healthcare, LLC	-
77.	Distribution Services Agreement, dated as of February 1, 2011, by and between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, Inc.	ASD Specialty Healthcare, LLC.	\$19,888.80
78.	Quality Agreement, dated as of April 4, 2019, by and between Acorda Therapeutics, Inc. and Cardinal Health 105, Inc.	Cardinal Health 105, Inc.	-
79.	U.S. Principal Party in Interest (USPPI) Affidavit and Power of Attorney, dated as of August 22, 2017, by and among Acorda Therapeutics, Inc.,	Cardinal Health 105 Inc. Cardinal Health 110, Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Cardinal Health 105 Inc. and Cardinal Health 110, Inc.		
80.	Letter re amendment to Operating Guidelines, dated as of March 3, 2020, by and between Cardinal Health Specialty Solutions and Acorda Therapeutics, Inc.	Cardinal Health Specialty Solutions	-
81.	Third Amendment to Distribution Agreement, dated as of September 28, 2012 by and between Acorda Therapeutics, Inc. and Cardinal Health 105, Inc.	Cardinal Health 105, Inc.	-
82.	Distribution Agreement, dated as of August 19, 2004, by and between Acorda Therapeutics, Inc. and Cardinal Health 105, Inc. f.k.a. Cardinal Health PTS, LLC	Cardinal Health 105, Inc. f.k.a. Cardinal Health PTS, LLC	-
83.	U.S. Principal Party in Interest (USPPI) Affidavit, dated as of January 8, 2019, by and between Acorda Therapeutics, Inc. and Cardinal Health 105, Inc.	Cardinal Health 105, Inc.	-
84.	U.S. Principal Party in Interest (USPPI) Affidavit, dated as of December 2, 2020, by and between Acorda Therapeutics, Inc. and Cardinal Health 105, Inc.	Cardinal Health 105, Inc.	-
85.	First Amendment to Distribution Agreement, dated as of July 26, 2005, by and between Cardinal Health PTS, LLC and Acorda Therapeutics, Inc.	Cardinal Health PTS, LLC	-
86.	Second Amendment to Distribution Agreement, dated as of January 22, 2010, by and between Cardinal Health 105, Inc. and Acorda Therapeutics, Inc.	Cardinal Health 105, Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
87.	Letter re Inbrija Return Goods Policy Notice Amendment, dated as of November 22, 2019, by and among Acorda Therapeutics, Inc., Express Scripts, Inc. and Accredo Health Group, Inc.	Express Scripts, Inc. Accredo Health Group, Inc.	-
88.	Product Purchase and Dispensing Agreement, dated as of April 15, 2016, by and between Acorda Therapeutics, Inc. and Accredo Health Group, Inc.	Accredo Health Group, Inc.	-
89.	4 th Amendment to Pharmacy Services Agreement, dated as of April 22, 2021, by and between Acorda Therapeutics, Inc. and Accredo Health Group, Inc.	Accredo Health Group, Inc.	-
90.	Second Amendment to Specialty Pharmacy Services Agreement, dated as of July 1, 2018, by and between Acorda Therapeutics, Inc. and Accredo Health Group, Inc.	Accredo Health Group, Inc.	-
91.	First Amendment to Specialty Pharmacy Services Agreement, dated as of April 20, 2018, by and between Acorda Therapeutics, Inc. and Accredo Health Group, Inc.	Accredo Health Group, Inc.	-
92.	Third Amendment to Specialty Pharmacy Data Services Agreement, dated as of June 25, 2015, by and between Acorda Therapeutics, Inc. and Accredo Health Group Inc.	Accredo Health Group, Inc.	-
93.	Third Amendment to Specialty Pharmacy Purchase and Dispensing Agreement, dated as of June 25, 2015, by and between Acorda Therapeutics, Inc. and Accredo Health Group Inc.	Accredo Health Group, Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
94.	Pharmacy Services Agreement dated as of April 15, 2016, by and between Acorda Therapeutics, Inc. and Accredo Health Group, Inc.	Accredo Health Group, Inc.	\$57,515.00
95.	Specialty Pharmacy Data Services Agreement dated as of February 26, 2010, by and between Acorda Therapeutics, Inc. and Accredo Health Group, Inc.	Accredo Health Group, Inc.	-
96.	Specialty Pharmacy Purchase and Dispensing Agreement, dated as of February 26, 2010, by and between Acorda Therapeutics, Inc. and Accredo Health Group, Inc.	Accredo Health Group, Inc.	-
97.	Third Amendment to Specialty Pharmacy Services Agreement, dated as of April 1, 2020, by and between Acorda Therapeutics, Inc. and Accredo Health Group, Inc.	Accredo Health Group, Inc.	-
98.	Second Amendment to Specialty Pharmacy Services Agreement, dated as of July 1, 2018, by and between Acorda Therapeutics, Inc. and Accredo Health Group, Inc.	Accredo Health Group, Inc.	-
99.	Draft Sixth Amendment to Specialty Pharmacy Purchase and Dispensing Agreement, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	\$33,714.73
100.	Third Amendment to Pharmacy Services Agreement, dated as of December 31, 2020, by and between Acorda Therapeutics, Inc. and Caremark, LLC.	Caremark, L.L.C.	-
101.	Letter re Inbrija Return Goods Policy Notice Amendment, dated as of November 22, 2019, by and between Acorda	Caremark, L.L.C.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Therapeutics, Inc. and Caremark, LLC.		
102.	Pharmacy Services Agreement, dated as of January 1, 2019, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	-
103.	Product Purchase and Dispensing Agreement, dated as of October 1, 2017, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	-
104.	Product Purchase and Dispensing Agreement, dated as of January 1, 2019, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	-
105.	Fourth Amendment to Pharmacy Services Agreement, dated as of May 1, 2021, by and between Acorda Therapeutics, Inc. And Caremark, L.L.C.	Caremark, L.L.C.	-
106.	First Amendment to Pharmacy Services Agreement, dated as of March 26, 2018, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	-
107.	Second Amendment to Pharmacy Services Agreement, dated as of May 1, 2020, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	-
108.	Pharmacy Services Agreement, dated as of October 1, 2017 , by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	-
109.	First Amendment to Pharmacy Services Agreement, dated as of March 26, 2018, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
110.	Third Amendment to Pharmacy Services Agreement, dated as of December 31, 2020, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	-
111.	Fourth Amendment to Pharmacy Services Agreement, dated as of May 1, 2021, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	-
112.	Fifth Amendment to Pharmacy Services Agreement, dated as of March 1, 2022, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	-
113.	Sixth Amendment to Pharmacy Services Agreement, dated as of May 9, 2022, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	-
114.	Second Amendment to Pharmacy Services Agreement, dated as of April 1, 2020, by and between Acorda Therapeutics, Inc. and Humana Pharmacy, Inc.	Humana Pharmacy, Inc.	-
115.	Third Amendment to Specialty Pharmacy Services Agreement, dated as of April 1, 2020, by and between Acorda Therapeutics, Inc. and Accredo Health Group, Inc.	Accredo Health Group, Inc.	-
116.	Second Amendment to Pharmacy Services Agreement, dated as of May 1, 2020, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	-
117.	Third Amendment to Specialty Pharmacy Services Agreement, dated as of April 1, 2020, by and between Acorda Therapeutics, Inc. and BriovaRx of Maine, Inc.	BriovaRx of Maine, Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
118.	Change Order #7 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of February 10, 2020, by and between Covance Market Access Services Inc. and Acorda Therapeutics, Inc.	Covance Market Access Services Inc.	-
119.	Change Order #8 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of May 11, 2020, by and between Covance Market Access Services Inc. and Acorda Therapeutics, Inc.	Covance Market Access Services Inc.	-
120.	Change Order #9 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of May 11, 2020, by and between Covance Market Access Services Inc. and Acorda Therapeutics, Inc.	Covance Market Access Services Inc.	-
121.	Change Order #10 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of May 27, 2020, by and between Covance Market Access Services Inc. and Acorda Therapeutics, Inc.	Covance Market Access Services Inc.	-
122.	Project Addendum #4 to the Master Market Access Services Agreement, dated as of June 22, 2018, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
123.	Master Specialty Pharmacy Services Agreement, dated as of July 19, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
124.	Project Addendum #2 to the Master Market Access Services Agreement, dated as of May 1, 2018, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
125.	Master Market Access Services Agreement, dated as of August 6, 2015, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
126.	Project Addendum #1 to the Master Market Access Services Agreement, dated as of September 2, 2015, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
127.	Project Addendum #3 to the Master Market Access Services Agreement, dated as of August 8, 2018, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
128.	Third Amendment to Pharmacy Services Agreement, dated as of February 15, 2023, by and between Acorda Therapeutics, Inc. and SterlingRX, Inc.	SterlingRX, Inc.	-
129.	Third Amendment to the Master Patient Support Hub Services Agreement, dated as of March 8, 2023, by and between Acorda Therapeutics, Inc. and RIS Rx.	RIS Rx	-
130.	Second Amendment to Master Direct Product Purchase and Dispensing Agreement, dated as of February 15, 2023, by and between Acorda Therapeutics, Inc. and SterlingRx, Inc.	SterlingRX, Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
131.	Inventory Amendment to Pharmacy Services Agreement, dated as of April 1, 2021, by and between Acorda Therapeutics, Inc. and Humana Pharmacy, Inc.	Humana Pharmacy, Inc.	-
132.	Letter re Inbrija Return Goods Policy Notice Amendment, dated as of November 22, 2019, by and between Acorda Therapeutics, Inc. and Humana Pharmacy, Inc.	Humana Pharmacy, Inc.	-
133.	Pharmacy Services Agreement, dated as of April 1, 2016, by and between Acorda Therapeutics, Inc. and Humana Pharmacy, Inc.	Humana Pharmacy, Inc.	-
134.	Product Purchase and Dispensing Agreement, dated as of April 1, 2016, by and between Acorda Therapeutics, Inc. and Humana Pharmacy, Inc.	Humana Pharmacy, Inc.	-
135.	Inbrija Product Attachment to Product Purchase and Dispensing Agreement, dated as of February 22, 2019, by and between Acorda Therapeutics, Inc. and Humana Pharmacy, Inc.	Humana Pharmacy, Inc.	-
136.	First Amendment to Pharmacy Services Agreement, dated as of December 1, 2017, by and between Acord Therapeutics, Inc. and Humana Pharmacy, Inc.	Humana Pharmacy, Inc.	-
137.	Second Amendment to Pharmacy Services Agreement, dated as of April 1, 2016, by and between Acorda Therapeutics, Inc. and Humana Pharmacy, Inc.	Humana Pharmacy, Inc.	-
138.	Inbrija Product Attachment to Pharmacy Services Agreement, dated as of March 21, 2019, by	Humana Pharmacy, Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	and between Acorda Therapeutics, Inc. and Humana Pharmacy, Inc.		
139.	Fourth Amendment to Specialty Pharmacy Services Agreement, dated as of May 1, 2021, by and between Acorda Therapeutics, Inc. and BriovaRx of Maine, Inc.	BriovaRx of Maine, Inc.	-
140.	Product Purchase and Dispensing Agreement, dated as of April 1, 2016, by and between Acorda Therapeutics, Inc. and BriovaRx of Maine Inc.	BriovaRx of Maine, Inc.	-
141.	Pharmacy Services Agreement, dated as of April 1, 2016, by and between Acorda, by and Therapeutics, Inc. and BriovaRx of Maine Inc.	BriovaRx of Maine, Inc.	\$68,380.00
142.	Specialty Pharmacy Data Services Agreement, dated as of January 8, 2015, by and between Acorda Therapeutics, Inc. and BriovaRx of Maine Inc.	BriovaRx of Maine, Inc.	-
143.	Letter re Inbrija Return Goods Policy Notice Amendment, dated as of November 22, 2019, by and between Acorda Therapeutics, Inc. and BriovaRx of Maine, Inc. and Optum Rx, Inc.	BriovaRx of Maine, Inc.	-
144.	First Amendment to Inbrija Product Attachment to Pharmacy Services Agreement, dated as of November 1, 2019, by and between Acorda Therapeutics, Inc. and BriovaRx of Maine, Inc.	BriovaRx of Maine, Inc.	-
145.	Third Amendment to Specialty Pharmacy Services Agreement, dated as of April 1, 2020, by and between Acorda	BriovaRx of Maine, Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Therapeutics, Inc. and BrioRx of Maine, Inc.		
146.	First Amendment to Specialty Pharmacy Services Agreement, dated as of March 1, 2018, by and between Acorda Therapeutics, Inc. and BrioRx of Maine, Inc.	BrioRx of Maine, Inc.	-
147.	Second Amendment to Specialty Pharmacy Services Agreement, dated as of March 1, 2018, by and between Acorda Therapeutics, Inc. and BrioRx of Maine, Inc.	BrioRx of Maine, Inc.	-
148.	Inbrija Product Attachment to Product Purchase and Dispensing Agreement, dated as of January 3, 2019, by and between Acorda Therapeutics, Inc. and BrioRx of Maine, Inc.	BrioRx of Maine, Inc.	-
149.	Product Purchase and Dispensing Agreement, dated as of August 31, 2020, by and between Acorda Therapeutics, Inc. and Walgreen Co.	Walgreen Co.	-
150.	Pharmacy Services Agreement, dated as of August 31, 2020, by and between Acorda Therapeutics, Inc. and Walgreen Co.	Walgreen Co.	\$80,951.54
151.	Pharmacy Services Agreement, dated as of April 1, 2021, by and between Acorda Therapeutics, Inc. and Walgreen Co.	Walgreen Co.	-
152.	Pharmacy Services Agreement, dated as of September 1, 2017, by and between Acorda Therapeutics, Inc. and Walgreen Co.	Walgreen Co.	\$41,540.00
153.	Product Purchase and Dispensing Agreement, dated as of September 1, 2017, by and between Acorda	Walgreen Co.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Therapeutics, Inc. and Walgreen Co.		
154.	Letter re Inbrija Return Goods Policy Notice Amendment, dated as of November 22, 2019, by and among Acorda Therapeutics, Inc. and Walgreens Co. and Walgreens Specialty Pharmacy, L.L.C.	Walgreens Co. Walgreens Specialty Pharmacy, L.L.C.	-
155.	Amendment No. 1 to Ampyra Pharmacy Services Agreement, dated as of April 28, 2020, by and between Acorda Therapeutics, Inc. and Walgreen Co.	Walgreen Co.	-
156.	First Amendment to Distribution Services Agreement, dated as of July 13, 2011, by and between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, Inc.	ASD Specialty Healthcare, Inc.	-
157.	Second Amendment to Distribution Services Agreement, dated as of November 14, 2012, by and between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, Inc.	ASD Specialty Healthcare, Inc.	-
158.	Third Amendment to Distribution Services Agreement, dated as of July 1, 2014, by and between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, Inc.	ASD Specialty Healthcare, Inc.	-
159.	Fourth Amendment to Distribution Services Agreement, dated as of November 4, 2014, by and between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, Inc.	ASD Specialty Healthcare, Inc.	-
160.	Fifth Amendment to Distribution Services Agreement, dated as of December 22, 2014, by and	ASD Specialty Healthcare, Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, Inc.		
161.	Sixth Amendment to Distribution Services Agreement, dated as of October 21, 2015, by and between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, Inc.	ASD Specialty Healthcare, Inc.	-
162.	Seventh Amendment to Distribution Services Agreement, dated as of February 1, 2019, by and between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, Inc.	ASD Specialty Healthcare, Inc.	-
163.	Eighth Amendment to Distribution Services Agreement, dated as of June 25, 2019, by and between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, Inc.	ASD Specialty Healthcare, Inc.	-
164.	Ninth Amendment to Distribution Services Agreement, dated as of September 6, 2019, by and between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, Inc.	ASD Specialty Healthcare, Inc.	-
165.	Amendment No. 1 to Master Specialty Pharmacy Services Agreement, dated as of August 1, 2020, by and between Acorda Therapeutics, Inc. and Covance Specialty Pharmacy LLC.	Covance Specialty Pharmacy LLC.	-
166.	Change Order #1 to Project Addendum #1 to the Master Specialty Pharmacy Services Agreement, dated as of January 1, 2022, by and between Labcorp Specialty Pharmacy LLC and Acorda Therapeutics, Inc.	Labcorp Specialty Pharmacy LLC	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
167.	Change Order #2 to Project Addendum #1 to the Master Specialty Pharmacy Services Agreement, dated as of January 20, 2022, by and between Labcorp Specialty Pharmacy LLC and Acorda Therapeutics, Inc.	Labcorp Specialty Pharmacy LLC	-
168.	Project Addendum #1 to the Master Market Access Services Agreement, dated as of July 19, 2018, by and between Acorda Therapeutics, Inc. and Covance Specialty Pharmacy LLC.	Covance Specialty Pharmacy LLC	-
169.	Project Addendum #2 to the Master Market Access Services Agreement, dated as of May 1, 2018, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
170.	Change Order #2 to Project Addendum #2 to the Master Market Access Services Agreement, dated as of October 30, 2018, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
171.	Change Order #2 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of April 15, 2019, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
172.	Change Order #2 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of April 15, 2019, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
173.	Change Order #3 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of May 22, 2019, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
174.	Change Order #4 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of June 15, 2019, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
175.	Change Order #7 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of February 10, 2020, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
176.	Change Order #8 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of May 11, 2020, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
177.	Change Order #9 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of May 11, 2020, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
178.	Change Order #1 to Project Addendum #2 and #3 to the Master Market Access Services Agreement, dated as of September 18, 2018, by and	Covance Market Access Services Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.		
179.	Change Order #12 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of April 1, 2021, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
180.	Change Order #10 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of May 27, 2020, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
181.	Change Order #11 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of July 17, 2020, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
182.	Change Order #6 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of February 24, 2020, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
183.	Change Order #1 to Project Addendum #1 to the Master Market Access Services Agreement, dated as of May 20, 2016, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
184.	Confidential Disclosure Agreement, dated as of May 26, 2017, by and between Covance Market Access	Covance Market Access Services Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Services Inc. and Acorda Therapeutics, Inc.		
185.	Project Addendum #4 to the Master Market Access Services Agreement, dated as of June 22, 2018, by and between Covance Market Access Services Inc. and Acorda Therapeutics, Inc.	Covance Market Access Services Inc.	\$310,036.54
186.	Master Market Access Services Agreement, dated as of August 6, 2015, by and between Covance Market Access Services Inc. and Acorda Therapeutics, Inc.	Covance Market Access Services Inc.	-
187.	Project Addendum #5 to Master Market Access Services Agreement, dated as of January 1, 2022, by and between Labcorp Peri-Approval and Commercialization Inc. and Acorda Therapeutics, Inc.	Labcorp Peri-Approval and Commercialization Inc.	-
188.	Project Addendum #1 to Master Market Access Services Agreement, dated as of September 2, 2015, by and between Covance Market Access Services Inc. and Acorda Therapeutics, Inc.	Covance Market Access Services Inc.	-
189.	Project Addendum #3, dated as of August 8, 2018, by and between Covance Market Access Services Inc. and Acorda Therapeutics, Inc.	Covance Market Access Services Inc.	-
190.	Change Order #2 to Project Addendum #1, dated as of January 1, 2024, by and between Fortrea Specialty Pharmacy LLC and Acorda Therapeutics, Inc.	Fortrea Specialty Pharmacy LLC	\$22,914.22
191.	Second Amendment to Master Specialty Pharmacy Services Agreement, dated as of May 1, 2023, by and between Fortrea	Fortrea Specialty Pharmacy LLC	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Specialty Pharmacy LLC and Acorda Therapeutics, Inc.		
192.	Amendment #1 to Master Specialty Pharmacy Services Agreement, dated as of August 1, 2020, by and between Covance Specialty Pharmacy LLC and Acorda Therapeutics, Inc.	Covance Specialty Pharmacy LLC	-
193.	Change Order #1 to Project Addendum #1, dated as of January 1, 2022, by and between Labcorp Specialty Pharmacy LLC and Acorda Therapeutics, Inc.	Labcorp Specialty Pharmacy LLC	-
194.	Master Specialty Pharmacy Services Agreement, dated as of July 19, 2018, by and between Acorda Therapeutics, Inc. and Fortrea Specialty Pharmacy LLC (f/k/a Covance Specialty Pharmacy LLC)	Fortrea Specialty Pharmacy LLC	-
195.	Project Addendum #1, dated as of July 19, 2018, by and between Covance Specialty Pharmacy LLC and Acorda Therapeutics, Inc.	Covance Specialty Pharmacy LLC	-
196.	Change Order #2 to Project Addendum #1, dated as of January 20, 2022, by and between Labcorp Specialty Pharmacy LLC and Acorda Therapeutics, Inc.	Labcorp Specialty Pharmacy LLC	-
197.	Specialty Pharmacy Purchase and Dispensing Agreement, dated as of September 28, 2023, by and between Acorda Therapeutics, Inc. and Gentry Health Services Inc.	Gentry Health Services Inc.	\$19,670.00
198.	Specialty Pharmacy Services Agreement, dated as of September 28, 2023, by and between Acorda Therapeutics, Inc. and Gentry Health Services Inc.	Gentry Health Services Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
199.	Trading Partner Account Set-up Form, dated as of September 19, 2019, by and between University of Wisconsin Hospitals and Clinics and Acorda Therapeutics, Inc.	University of Wisconsin Hospitals and Clinics	-
200.	Inflation Agreement, dated as of July 1, 2019, by and between Acorda Therapeutics, Inc. and Ascent Health Services LLC	Ascent Health Services LLC	-
201.	Inflation Agreement, dated as of July 1, 2019, by and between Acorda Therapeutics, Inc. and Express Scripts, Inc.	Express Scripts, Inc.	-
202.	Medicare Part D Rebate Inflation Agreement, dated as of July 1, 2020, by and between Acorda Therapeutics, Inc. and Express Scripts Senior Care Holdings, Inc.	Express Scripts Senior Care Holdings, Inc.	-
203.	Amendment to Distribution Agreement for Spain, dated as of November 8, 2021, by and between Esteve Pharmaceuticals, S.A. and Acorda Therapeutics, Inc.	Esteve Pharmaceuticals, S.A.	-
204.	Distribution Agreement, dated as of July 20, 2021, by and between Acorda Therapeutics, Inc. and Esteve Pharmaceuticals, S.A.	Esteve Pharmaceuticals, S.A.	-
205.	Supply Agreement, dated as of May 3, 2023, by and between Acorda Therapeutics, Inc. and Hangzhou Chance Pharmaceuticals Co., Ltd.	Hangzhou Chance Pharmaceuticals Co., Ltd.	-
206.	Exclusive Distribution Agreement, dated as of May 3, 2023, by and between Acorda Therapeutics, Inc. and Hangzhou Chance Pharmaceuticals Co., Ltd.	Hangzhou Chance Pharmaceuticals Co., Ltd.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
207.	Distribution Agreement, dated as of November 8, 2021, by and between Acorda Therapeutics, Inc. and Esteve Pharmaceuticals GmbH	Esteve Pharmaceuticals GmbH	-
208.	Supply Agreement, dated as of November 8, 2021, by and between Acorda Therapeutics, Inc. and Esteve Pharmaceuticals GmbH	Esteve Pharmaceuticals GmbH	-
209.	Distribution Agreement, dated as of May 11, 2022, by and between Acorda Therapeutics, Inc. and Pharma Consulting Group, S.A.	Pharma Consulting Group, S.A.	-
210.	Supply Agreement, dated as of May 11, 2022, by and between Acorda Therapeutics, Inc. and Pharma Consulting Group, S.A.	Pharma Consulting Group, S.A.	-
211.	Supply Agreement, dated as of July 20, 2021, by and between Acorda Therapeutics, Inc. and Esteve Pharmaceuticals, S.A.	Esteve Pharmaceuticals, S.A.	-
212.	Amendment to Distribution Agreement for Germany, dated as of May 23, 2023, by and between Esteve Pharmaceuticals GmbH and Acorda Therapeutics, Inc.	Esteve Pharmaceuticals, GmbH	-
213.	Amendment to Supply Agreement for Germany, dated as of May 23, 2023, by and between Esteve Pharmaceuticals GmbH and Acorda Therapeutics, Inc.	Esteve Pharmaceuticals, GmbH	-
214.	First Amendment to the Supply Agreement, dated as of May 10, 2022, by and between Esteve Pharmaceuticals GmbH and Acorda Therapeutics, Inc.	Esteve Pharmaceuticals, GmbH	-
215.	Quality Agreement, dated as of September 19, 2022, by and between Acorda Therapeutics Ireland Limited and Adoh B.V.	Adoh B.V.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
216.	General Service Agreement dated as of October 16, 2018 between Acorda Therapeutics, Inc., Acorda Therapeutics Ireland Limited and Adoh B.V.	Adoh B.V.	\$14,524.17
217.	Importer Agreement, dated as of August 4, 2021, by and between Acorda Therapeutics, Inc. and MedEnvoy Global B.V.	MedEnvoy Global B.V.	-
218.	Safety Data Exchange Agreement, dated as of November 30, 2023, by and among Acorda Therapeutics, Inc., Esteve Pharmaceuticals GMBH and Esteve Pharmaceuticals S.A.	Esteve Pharmaceuticals GMBH Esteve Pharmaceuticals S.A.	-
219.	Third Amendment to the Distribution Agreement for Germany, dated as of December 14, 2023, by and between Esteve Pharmaceuticals GmbH and Acorda Therapeutics, Inc.	Esteve Pharmaceuticals GMBH	-
220.	Second Amendment to the Distribution Agreement for Germany, dated as of December 14, 2023, by and between Esteve Pharmaceuticals GmbH and Acorda Therapeutics, Inc.	Esteve Pharmaceuticals GmbH	-
221.	First Amendment to the Medicare Part D Program Rebate Agreement, dated as of January 1, 2022, by and between CVS Caremark Part D Services, LLC and Acorda Therapeutics, Inc.	CVS Caremark Part D Services, LLC	\$141,601.71
222.	Medicare Part D Rebate Agreement, dated as of January 1, 2016, by and between Acorda Therapeutics, Inc. and OptumRx, Inc.	OptumRx, Inc.	-
223.	Rebate Agreement, dated as of January 1, 2013, by and	OptumRx, Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Acorda Therapeutics, Inc. and OptumRx, Inc.		
224.	Sixth Amendment to the Medicare Part D Rebate Agreement, dated as of January 1, 2023, by and between OptumRx, Inc. and Acorda Therapeutics, Inc.	OptumRx, Inc.	\$109,300.76
225.	First Amendment to the Master Services Agreement, dated as of March 9, 2023, by and between Riparian LLC and Acorda Therapeutics, Inc.	Riparian LLC	-
226.	Master Services Agreement, dated as of January 16, 2019, by and between Acorda Therapeutics, Inc. and TrialCard Incorporated	TrialCard Incorporated	-
227.	Master Services Agreement, dated as of April 15, 2020, by and between Acorda Therapeutics, Inc. and Riparian, LLC	Riparian LLC	-
228.	Statement of Work #3, dated as of September 28, 2023, by and between Riparian LLC and Acorda Therapeutics, Inc.	Riparian LLC	-
229.	TrialCard Statement of Work: 2023 Engage HCP PTR Program (Inside Sales Program), dated as of January 1, 2023, by and between TrialCard Incorporated and Acorda Therapeutics, Inc.	TrialCard Incorporated	-
230.	First Amendment to the Master Services Agreement, dated as of July 15, 2022, by and between TrialCard Incorporated and Acorda Therapeutics, Inc.	TrialCard Incorporated	-
231.	TrialCard Statement of Work Inbrija Copay Program Change Order Number 6, dated as of January 1, 2023, by and between TrialCard	TrialCard Incorporated	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Incorporated and Acorda Therapeutics, Inc.		
232.	Third Amendment to the Master Services Agreement, dated as of November 15, 2023, by and between TrialCard Incorporated and Acorda Therapeutics, Inc.	TrialCard Incorporated	-
233.	TrialCard Statement of Work Change Order Number 1: Inbrija Co-pay Program, dated as of September 5, 2019, by and between TrialCard Incorporated and Acorda Therapeutics, Inc.	TrialCard Incorporated	-
234.	TrialCard Statement of Work Change Order Number 2: Inbrija Co-pay Program, dated as of February 1, 2020, by and between TrialCard Incorporated and Acorda Therapeutics, Inc.	TrialCard Incorporated	-
235.	TrialCard Statement of Work: Co-pay Services: Inbrija Co-pay Program, dated as of January 16, 2019, by and between TrialCard Incorporated and Acorda Therapeutics, Inc.	TrialCard Incorporated	-
236.	Statement of Work: 2024 Inbrija Copay Program, dated as of January 1, 2024, by and between Mercalis Inc. and Acorda Therapeutics, Inc.	Mercalis Inc.	-
237.	TrialCard Statement of Work Change Order Number 3: Inbrija Co-pay Program, dated as of May 8, 2020, by and between TrialCard Incorporated and Acorda Therapeutics, Inc.	TrialCard Incorporated	-
238.	Second Amendment to the Master Services Agreement, dated as of January 11, 2023, by and between TrialCard	TrialCard Incorporated	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Incorporated and Acorda Therapeutics, Inc.		
239.	TrialCard Statement of Work Inbrija Copay Program: Change Order Number 7, dated as of March 24, 2022, by and between TrialCard Incorporated and Acorda Therapeutics, Inc.	TrialCard Incorporated	-
240.	Statement of Work: Acorda Therapeutics, Inc. 2024 Inside Sales Program, dated as of January 1, 2024, by and between Mercalis Inc. and Acorda Therapeutics, Inc.	Mercalis Inc.	-
241.	TrialCard Statement of Work: Ampyra Copay Assistance Program, dated as of August 1, 2022, by and between TrialCard Incorporated and Acorda Therapeutics, Inc.	TrialCard Incorporated	-
242.	TrialCard Statement of Work Change Order Number 4: Inbrija Co-pay Program, dated as of March 1, 2021, by and between TrialCard Incorporated and Acorda Therapeutics, Inc.	TrialCard Incorporated	-
243.	TrialCard Statement of Work Change Order Number 5: Inbrija Co-pay Program, dated as of April 2, 2021, by and between TrialCard Incorporated and Acorda Therapeutics, Inc.	TrialCard Incorporated	-
244.	Confidential Disclosure Agreement, dated as of May 28, 2009, by and among Regis Technologies, Inc., Bayer HealthCare Pharmaceuticals Inc. and Acorda Therapeutics, Inc.	Regis Technologies, Inc., Bayer HealthCare Pharmaceuticals Inc.	-
245.	Amendment #1 to Master Services Agreement, dated as of March 5, 2010, by and	Regis Technologies, Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Regis Technologies, Inc. and Acorda Therapeutics, Inc.		
246.	Amendment #2 to Master Services Agreement, dated as of March 4, 2012, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies, Inc.	-
247.	Amendment #3 to Master Services Agreement, dated as of March 3, 2013, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies, Inc.	-
248.	Confidential Disclosure Agreement, dated as of February 7, 2008, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies, Inc.	-
249.	Confidential Disclosure Agreement, dated as of June 3, 2009, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies, Inc.	-
250.	Consent Letter, dated as of May 18, 2009, by and among Regis Technologies, Inc., SmithKline Beecham Corporation, and Acorda Therapeutics, Inc.	Regis Technologies, Inc. SmithKline Beecham Corporation	-
251.	Master Service Agreement, dated as of May 5, 2009, by and between Acorda Therapeutics, Inc. and Regis Technologies Inc.	Regis Technologies Inc.	-
252.	Mutual Confidentiality and Non-Disclosure Agreement, dated as of October 1, 2009, by and among J-Star Research, Regis Technologies, Inc. and Acorda Therapeutics, Inc.	J-Star Research Regis Technologies, Inc.	-
253.	Project Addendum #10, dated as of July 25, 2011, by and	Regis Technologies Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Regis Technologies, Inc. and Acorda Therapeutics, Inc.		
254.	Project Addendum #11, dated as of March 6, 2012, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
255.	Project Addendum #2, dated as of March 9, 2009, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
256.	Project Addendum #3, dated as of May 15, 2009, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
257.	Project Addendum #4, dated as of August 15, 2009, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
258.	Project Addendum #5, dated as of August 15, 2009, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
259.	Project Addendum #6, dated as of September 15, 2009, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
260.	Project Addendum #8, dated as of May 7, 2010, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
261.	Project Addendum #9, dated as of April 6, 2011, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
262.	Project Addendum #9, dated as of September 27, 2010, by and	Regis Technologies Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Regis Technologies, Inc. and Acorda Therapeutics, Inc.		
263.	Quality Agreement, dated as of April 1, 2011, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
264.	Amendment #4 to Master Services Agreement, dated as of October 9, 2018, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
265.	Certificate of Analysis, dated as of April 1, 1987, prepared by Regis Technologies, Inc.	Regis Technologies Inc.	-
266.	Supply Agreement, dated as of April 1, 2011, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
267.	Amendment #5 to Master Services Agreement, dated as of January 29, 2024, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
268.	Letter Agreement on Confidential Treatment of Third Party Transaction Information, dated as of July 14, 2017, by and among Sharp Corporation, Alkermes Pharma Ireland Limited, and Acorda Therapeutics, Inc.	Sharp Corporation Alkermes Pharma Ireland Limited	-
269.	Four-Way Confidentiality Agreement dated as of July 18, 2017 between Acorda Therapeutics, Inc., Covis Pharma B.V., Alkermes Pharma Ireland Limited and Sharp Corporation	Covis Pharma B.V. Alkermes Pharma Ireland Limited Sharp Corporation	-
270.	Agreement on Confidential Treatment of Third Party Transaction Information, dated as of July 13, 2017, by and	Alkermes Pharma Ireland Limited	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Alkermes Pharma Ireland Limited and Acorda Therapeutics, Inc.		
271.	Letter Agreement on Subcontract of Certain Packaged Product Release and Quality Responsibilities by Alkermes to Acorda for Ampyra, Zanaflex and Tizanidine, dated as of May 5, 2016, by and between Alkermes Pharma Ireland Limited and Acorda Therapeutics, Inc.	Alkermes Pharma Ireland Limited	-
272.	Contract Packaging Quality Agreement, dated as of May 12, 2016, by and among Acorda Therapeutics, Inc., Sharp Corporation and Alkermes Pharma Ireland Limited	Alkermes Pharma Ireland Limited	-
273.	Confidential Disclosure Agreement, dated as of December 13, 2012, by and between Sharp Corporation and Acorda Therapeutics, Inc.	Sharp Corporation	-
274.	Packaging and Supply Agreement, dated as of December 31, 2016, by and between Acorda Therapeutics, Inc. and Sharp Packaging Services, LLC	Sharp Packaging Services, LLC	-
275.	Quality Agreement, dated as of October 16, 2017, by and between Acorda Therapeutics, Inc. and Sharp Corporation	Sharp Corporation	-
276.	First Amendment to the Packaging and Supply Agreement, dated as of December 13, 2022, by and between Sharp Packaging Services, LLC and Acorda Therapeutics, Inc.	Sharp Packaging Services, LLC	-
277.	Quality Agreement, dated as of November 28, 2018, by and	Qualicaps, Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Qualicaps, Inc. and Acorda Therapeutics, Inc.		
278.	Amendment No. 1 to Commercial Quality Agreement, dated as of November 18, 2016, by and between Acorda Therapeutics, Inc. and Patheon, Inc.	Patheon, Inc.	-
279.	Change Order Pursuant to Section 9 of the Development and Manufacturing Services Agreement, dated as of June 18, 2015, by and between Acorda Therapeutics, Inc. and Patheon Biologics (NJ) LLC	Patheon Biologics (NJ) LLC	-
280.	Manufacturing Service Agreement, dated as of September 30, 2010, by and between Acorda Therapeutics, Inc. and Patheon Inc.	Patheon Inc.	-
281.	Master Agreement for Pharmaceutical Development Services, dated as of September 22, 2011, by and between Acorda Therapeutics, Inc. and Patheon Inc.	Patheon Inc.	-
282.	Change Order Pursuant to Section 9 of the Development and Manufacturing Services Agreement, dated as of September 14, 2015, by and between Acorda Therapeutics, Inc. and Patheon Biologics (NJ) LLC	Patheon Biologics (NJ) LLC	-
283.	Fampridine Tablets (10mg, 15mg, 20mg, 25mg) Technical Transfer Program Proposal for Commercial Registration, Proposal No. ELN-FQ-0001-1002-R4, dated as of February 26, 2003, by and between Patheon, Inc. and Acorda Therapeutics, Inc.	Patheon Inc.	-
284.	Proposal SC_AA1_09032016-01 Additional Upstream	Patheon Biologics (NJ) LLC	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Process Development, dated as of August 26, 2016, by and between Patheon Biologics (NJ) LLC and Acorda Therapeutics, Inc.		
285.	Fampridine-SR Tablets: Validation Services Pricing Proposal and Terms and Conditions, Proposal #: 1707-FTR1-0400-0509-R0, dated as of September 14, 2009, by and between Patheon Inc. and Acorda Therapeutics, Inc.	Patheon Inc.	-
286.	Ampyra 10 mg ER Tablets 2012 Annual Stability Studies, Proposal #: ACD-CTR1-05-0413-R0, dated as of June 17, 2013, by and between Patheon Inc. and Acorda Therapeutics, Inc.	Patheon Inc.	-
287.	Ampyra 10 mg ER Tablets 2013 Annual Stability Studies – Lot MBZN made with 4-AP (Lot 234-35-2), Proposal #: ACD-CTR1-06-0513-R0, dated as of June 17, 2013, by and between Patheon Inc. and Acorda Therapeutics, Inc.	Patheon Inc.	-
288.	Ampyra 10 mg ER Tables, 2015 Annual Stability Studies, Proposal #: ACD-CTR1-13-0615-R0, dated as of July 20, 2015, by and between Patheon Inc. and Acorda Therapeutics, Inc.	Patheon Inc.	-
289.	Quality Agreement Commercial Product, dated as of September 30, 2010, by and between Acorda Therapeutics, Inc. and Patheon Inc.	Patheon Inc.	-
290.	Manufacturing and Supply Agreement, dated as of January 16, 2020, by and between Acorda Therapeutics, Inc. and SMC Ltd.	SMC Ltd.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
291.	Amendment #1 to Manufacturing and Supply Agreement, dated as of March 31, 2020, by and between SMC, Ltd. and Acorda Therapeutics, Inc.	SMC, Ltd.	-
292.	Quality Agreement, dated as of June 2, 2021, by and between Acorda Therapeutics, Inc. and SMC Ltd.	SMC Ltd.	-
293.	Amendment #1 to Master Services Agreement, dated as of September 29, 2015, by and between The Hibbert Group and Acorda Therapeutics, Inc.	The Hibbert Group	-
294.	Amendment #2 to Master Services Agreement, dated as of October 25, 2018, by and between The Hibbert Group and Acorda Therapeutics, Inc.	The Hibbert Group	-
295.	Amendment #3 to Master Services Agreement, dated as of November 10, 2020, by and between The Hibbert Group and Acorda Therapeutics, Inc.	The Hibbert Group	-
296.	Quality Agreement, dated as of January 22, 2019, by and between Acorda Therapeutics, Inc. and the Hibbert Company Inc. d/b/a the Hibbert Group	The Hibbert Company Inc. d/b/a the Hibbert Group	-
297.	Master Service Agreement, dated as of September 18, 2014, by and between Acorda Therapeutics, Inc. and the Hibbert Company Inc. d/b/a the Hibbert Group	Hibbert Company Inc. d/b/a the Hibbert Group	\$25,848.70
298.	Amendment #4 to Master Services Agreement, dated as of January 31, 2024, by and between the Hibbert Company Inc. and Acorda Therapeutics, Inc.	The Hibbert Group	-
299.	Quality Agreement, dated as of October 12, 2021, by and	The Hibbert Group	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between The Hibbert Group and Acorda Therapeutics, Inc.		
300.	Quality Agreement, dated as of May 10, 2022, by and among Esteve Pharmaceuticals S.A., Esteve Pharmaceuticals GmbH and Acorda Therapeutics, Inc.	Esteve Pharmaceuticals S.A. Esteve Pharmaceuticals GmbH	-
301.	SC_AA1_09032016-01 Additional Upstream Process Development, dated as of August 26, 2016, by and between Patheon Biologics (NJ) LLC and Acorda Therapeutics, Inc.	Patheon Biologics (NJ) LLC	-
302.	Master Services Agreement, dated as of August 1, 2017, by and between Radius Product Development, Inc. and Acorda Therapeutics, Inc.	Radius Product Development, Inc.	-
303.	Amendment #1 to Master Services Agreement, dated as of July 26, 2019, by and between Radius Product Development, Inc. and Acorda Therapeutics, Inc.	Radius Product Development, Inc.	-
304.	Termination Letter, dated as of January 8, 2024, by and between Acorda Therapeutics, Inc. and Biogen International GMBH	Biogen International GMBH	-
305.	Transaction Document Form # M-4297, undated, by and between International Business Machines Corporation and Acorda Therapeutics, Inc.	International Business Machines Corporation	-
306.	Cloud Services Agreement, undated, by and between International Business Machines Corporation and Acorda Therapeutics, Inc.	International Business Machines Corporation	-
307.	Project Addendum #12, dated as of January 1, 2023, by and between Roadmap	Roadmap Technologies, Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Technologies, Inc. and Acorda Therapeutics, Inc.		
308.	Project Addendum #13, dated as of January 1, 2023, by and between Roadmap Technologies, Inc. and Acorda Therapeutics, Inc.	Roadmap Technologies, Inc.	-
309.	Master Service Agreement, dated as of April 29, 2014, by and between Acorda Therapeutics, Inc. and Roadmap Technologies, Inc.	Roadmap Technologies, Inc.	-
310.	Project Addendum #14, dated as of January 1, 2024, by and between Roadmap Technologies, Inc. and Acorda Therapeutics, Inc.	Roadmap Technologies, Inc.	-
311.	Project Addendum #15, dated as of January 1, 2024, by and between Roadmap Technologies, Inc. and Acorda Therapeutics, Inc.	Roadmap Technologies, Inc.	-
312.	Cooperation Agreement, dated as of May 10, 2022, by and between Acorda Therapeutics Ireland Limited and ACS PharmaProtect GmbH	ACS PharmaProtect GmbH	-
313.	Quality Agreement, dated as of August 1, 2022, by and between Acorda Therapeutics Ireland Limited and Adoh B.V.	Adoh B.V.	-
314.	General Service Agreement, dated as of October 16, 2018, by and between Acorda Therapeutics Ireland Limited and Adoh B.V.	Adoh B.V.	-
315.	Framework Agreement, dated as of March 3, 2023, by and between Ron Cohen in representation of Acorda Therapeutics Ireland Limited and Sistema Español de Verificacion de Medicamentos, S.L.	Sistema Español de Verificacion de Medicamentos, S.L.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
316.	Safety Agreement, dated as of June 2, 2020, by and between Acorda Therapeutics Ireland Limited and Adoh B.V.	Adoh B.V.	-
317.	Order Form, dated as of December 1, 2018, by and between Acorda Therapeutics, Inc. and Klick Inc.	Klick Inc.	-
318.	Order / Quote (Number: Q-28352), dated as of August 11, 2023, from Acorda Therapeutics, Inc. to Bigtincan Mobile Pty Ltd	Bigtincan Mobile Pty Ltd	-
319.	Omnicia Agreement, dated as of May 19, 2020, by and between Acorda Therapeutics, Inc. and Omnicia, Inc.	Omnicia, Inc.	-
320.	Confidential Disclosure Agreement, dated as of January 26, 2023, by and between Acorda Therapeutics, Inc. and Apollo Rx LLC	Apollo Rx LLC	-
321.	Project Addendum #1 to the Master Services Agreement, dated as of February 1, 2023, by and between Acorda Therapeutics, Inc. and Apollo Rx LLC	Apollo Rx LLC	-
322.	Master Services Agreement, dated as of February 1, 2023, by and between Acorda Therapeutics, Inc. and Apollo Rx LLC	Apollo Rx LLC	\$70,000.00
323.	Agreement for Authorised Representative Services, dated as of August 22, 2022, by and between Acorda Therapeutics, Inc. and Donawa Lifescience	Donawa Lifescience	-
324.	Master Services Agreement, dated as of October 30, 2018, by and between Acorda Therapeutics, Inc. and Clinipace, Inc. d/b/a Caidya	Clinipace, Inc. d/b/a Caidya	-
325.	Contract, dated as of March 1, 2023, by and between Acorda	BSI Group The Netherlands B.V.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Therapeutics, Inc. and BSI Group The Netherlands B.V.		
326.	Master Consulting Agreement, dated as of August 19, 2021, by and between Acorda Therapeutics, Inc. and Gilani, LLC	Gilani, LLC	-
327.	Letter Agreement, dated as of April 14, 2021, by and between iPharma Labs, Inc. and Acorda Therapeutics, Inc.	iPharma Labs, Inc.	-
328.	Change Order No. 2 to the Original SOW, dated as of January 11, 2024, by and between Acorda Therapeutics, Inc. and Model N, Inc.	Model N, Inc.	-
329.	Change Order No. 1 to the Original SOW, dated as of October 19, 2022, by and between Acorda Therapeutics, Inc. and Model N, Inc.	Model N, Inc.	-
330.	Engagement Letter, dated as of January 7, 2021, by and between Acorda Therapeutics, Inc. and Model N, Inc.	Model N, Inc.	-
331.	Mutual Nondisclosure Agreement, dated as of November 8, 2012, by and between Acorda Therapeutics, Inc. and Model N, Inc.	Model N, Inc.	-
332.	Model N Business Services Statement of Work for Acorda Therapeutics, Inc., dated as of December 20, 2021, by and between Acorda Therapeutics, Inc. and Model N, Inc.	Model N, Inc.	-
333.	Co-Operation Agreement, dated as of March 25, 2024, by and among Acorda Therapeutics, Inc., RubiePharm Arzneimittel GmbH, Pharma Consulting Group, S.A. and Biopas Mexico, S.A. de C.V.	RubiePharm Arzneimittel GmbH Pharma Consulting Group, S.A. Biopas Mexico, S.A. de C.V.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
334.	Amendment #1 to Project Addendum #1, dated as of June 20, 2014, by and between Acorda Therapeutics, Inc. and Dohmen Life Science Services, LLC	Dohmen Life Science Services, LLC	-
335.	Amendment #1 to Project Addendum #3, dated as of September 13, 2016, by and between Acorda Therapeutics, Inc. and Dohmen Life Science Services, LLC as successor-in-interest to the The F. Dohmen Co.	Dohmen Life Science Services, LLC	-
336.	Amendment #2 to Project Addendum #3, dated as of November 6, 2018, by and between Acorda Therapeutics, Inc. and Dohmen Life Science Services, LLC as successor-in-interest to the The F. Dohmen Co.	Dohmen Life Science Services, LLC	-
337.	Amendment #3 to Project Addendum #3, dated as of March 28, 2019, by and between Acorda Therapeutics, Inc. and Eversana Life Science Services, LLC (formerly known as Dohmen Life Science Services, LLC)	Eversana Life Science Services, LLC (formerly known as Dohmen Life Science Services, LLC)	\$107,604.04
338.	Assignment and Assumption Agreement, dated as of June 20, 2014, by and between The F. Dohmen Co. and Dohmen Life Science Services, LLC, and consented to by Acorda Therapeutics, Inc.	The F. Dohmen Co. Dohmen Life Science Services, LLC	-
339.	Master Services Agreement, dated as of March 22, 2013, by and between Acorda Therapeutics, Inc. and The F. Dohmen Co. (d/b/a MedComm Solutions)	The F. Dohmen Co. (d/b/a MedComm Solutions)	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
340.	Project Addendum #1, dated as of March 22, 2013, by and between Acorda Therapeutics, Inc. and The F. Dohmen Co. (d/b/a MedComm Solutions)	The F. Dohmen Co. (d/b/a MedComm Solutions)	-
341.	Project Addendum #2, dated as of March 3, 2015, by and between Acorda Therapeutics, Inc. and Dohmen Life Science Services, LLC	Dohmen Life Science Services, LLC	-
342.	Project Addendum #3, dated as of January 1, 2016, by and between Acorda Therapeutics, Inc. and Dohmen Life Science Services, LLC	Dohmen Life Science Services, LLC	-
343.	Settlement Agreement, dated as of January 12, 2018, by and between Acorda Therapeutics, Inc. and Micro USA Inc.	Micro USA Inc.	-
344.	Settlement Agreement, dated as of January 12, 2018, by and between Acorda Therapeutics, Inc. and Actavis Laboratories FL, Inc.	Actavis Laboratories FL, Inc.	-
345.	Settlement Agreement, dated as of December 15, 2015, by and between Acorda Therapeutics, Inc. and Aurobindo Pharma USA.	Aurobindo Pharma USA.	-
346.	Settlement Agreement, dated as of February 8, 2017, by and between Acorda Therapeutics, Inc. and Apotex Inc.	Apotex Inc.	-
347.	Settlement Agreement, dated as of August 11, 2016, by and between Acorda Therapeutics, Inc. and Accord Healthcare, Inc.	Accord Healthcare, Inc.	-
348.	Settlement Agreement, dated as of January 15, 2016, by and between Acorda Therapeutics, Inc. and Par Pharmaceuticals Inc.	Par Pharmaceuticals Inc.	-
349.	Settlement Agreement, dated as of July 27, 2018, by and	Mylan Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Acorda Therapeutics, Inc. and Mylan Inc.		
350.	Settlement Agreement, dated as of October 15, 2015, by and between Acorda Therapeutics, Inc. and Sun Pharmaceuticals Industries Limited.	Sun Pharmaceuticals Industries Limited.	-
351.	Inbrija® Ambassador Program Agreement, dated May 17, 2021, by and between Acorda Therapeutics, Inc. and Rachel Weinberger, as amended.	Rachel Weinberger	-
352.	Inbrija® Ambassador Program Agreement, dated September 27, 2019, by and between Acorda Therapeutics, Inc. and Stephanie Cook, as amended	Stephanie Cook	-
353.	Inbrija™ Ambassador Program Agreement, dated November 6, 2019, by and between Acorda Therapeutics, Inc. and John Baumann.	John Baumann	-
354.	Inbrija® Ambassador Program Agreement, dated April 6, 2020, by and between Acorda Therapeutics, Inc. and James Gaddis, as amended.	James Gaddis	-
355.	Inbrija® Ambassador Program Agreement, dated September 6, 2019, by and between Acorda Therapeutics, Inc. and Robert Harmon, as amended.	Robert Harmon	-
356.	INBRIJA™ Ambassador Program Agreement dated September 9, 2019, as amended	Bettina Chavanne	-
357.	INBRIJA® Patient Video Program Agreement dated October 2, 2023	Kay Henry	-
358.	Care Partner Agreement dated October 2, 2023	Charles Henry	-
359.	INBRIJA® Care Partner Program Agreement dated June 3, 2022, as amended	Kristi Gaddis	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
360.	INBRIJA® Care Partner Program Agreement dated June 6, 2022	Bernadette Baumann	-
361.	Authorization to Reproduce Video and Likeness Release dated October 6, 2019 signed by Cecily Harmon	Cecily Harmon	-
362.	Master Consulting Agreement, dated September 12, 2016, by and between Acorda Therapeutics, Inc. and Gary Rafaloff, as amended.	Gary Rafaloff	-
363.	Master Consulting Agreement, dated July 2, 2015, by and between Acorda Therapeutics, Inc. and Peter LeWitt, as amended. Master Consulting Agreement, dated June 1, 2020, by and between Acorda Therapeutics, Inc. and Peter A. LeWitt, MD, as amended.	Peter LeWitt	-
364.	Master Consulting Agreement, dated as of January 12, 2021, by and between Acorda Therapeutics, Inc. and Julie Schwartzbard, MD, as amended.	Julie Schwartzbard	-
365.	Master Consulting Agreement, dated as of January 15, 2021, by and between Acorda Therapeutics, Inc. and Jennifer Durphy, as amended.	Jennifer Durphy	\$650.00
366.	Master Consulting Agreement, dated as of September 10, 2020, by and between Acorda Therapeutics, Inc. and Ray Dorsey, MD, as amended.	Ray Dorsey	-
367.	Master Consulting Agreement, dated as of September 10, 2020, by and between Acorda Therapeutics, Inc. and Rajeev Kumar, MD, as amended.	Rajeev Kumar	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
368.	Master Consulting Agreement, dated as of November 25, 2020, by and between Acorda Therapeutics, Inc. and Ronald F. Pfeiffer, as amended.	Ronald Pfeiffer	-
369.	Master Consulting Agreement, dated as of December 3, 2020, by and between Acorda Therapeutics, Inc. and Dr. Salima Brillman, as amended.	Salima Brillman	-
370.	<ul style="list-style-type: none"> Letter agreement titled "Re: Letter regarding Services for Presentation for Consumer Programs for Ampyra ("Letter")", dated as of May 11, 2010, by Acorda Therapeutics, Inc. and acknowledged by Susan Zurndorfer. Consulting Agreement, dated as of May 10, 2007, by and between Acorda Therapeutics, Inc. and Susan Zurndorfer. Letter agreement titled "Re: Letter for Services for Photograph ("Letter")", dated as of March 7, 2011, by Acorda Therapeutics, Inc. and acknowledged by Susan Zurndorfer. Master Consulting Agreement, dated as of March 25, 2013, by and between Acorda Therapeutics, Inc. and Susan Zurndorfer, as amended. 	Susan Zurndorfer	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
371.	<ul style="list-style-type: none"> • Parent's or Guardian's Consent, dated as of February 1, 2012, by Lisa Green • Letter agreement titled "Re: Letter Agreement for Participation in Patient Testimonials, an Audio News Releases and a Matte Release", dated as of August 17, 2011, by Acorda Therapeutics, Inc. and acknowledged by Lisa Green. • Letter agreement titled "Re: Letter Agreement for Participation in Patient Testimonials, an Audio News Releases and a Matte Release", dated as of September 7, 2012, by Acorda Therapeutics, Inc. and acknowledged by Lisa Green. 	Lisa Green	-
372.	Non-Healthcare Professional Ambassador Agreement, dated January 1, 2020, by and between Acorda Therapeutics, Inc. and Zarela Martinez, as amended	Zarela Martinez	-
373.	Non-Healthcare Professional Consulting Agreement dated September 5, 2018	Sarah Diaz	-
374.	Non-Healthcare Professional Consulting Agreement dated January 9, 2019	Gustavo Pavon	-
375.	Non-Healthcare Professional Consulting Agreement dated January 9, 2019	Linda Berghoff	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
376.	Non-Healthcare Professional Consulting Agreement, dated September 5, 2018, by and between Acorda Therapeutics, Inc. and John Pelchat.	John Pelchat	-
377.	Non-Healthcare Professional Consulting Agreement, dated September 5, 2018, by and between Acorda Therapeutics, Inc. and Jennifer Parkinson	Jennifer Parkinson	-
378.	Non-Healthcare Professional Consulting Agreement, dated September 5, 2018, by and between Acorda Therapeutics, Inc. and Steve Peters.	Steve Peters	-
379.	Consultant Agreement (Non-HCP), dated June 1, 2016, by and between Acorda Therapeutics, Inc. and Lynn Hagerbrant, as amended.	Lynn Hagerbrant	-
380.	Non-Healthcare Professional Consulting Agreement, dated February 8, 2018, by and between Acorda Therapeutics, Inc. and Michael Bergamo.	Michael Bergamo	-
381.	<ul style="list-style-type: none"> • Consultant Agreement (Non-HCP), dated June 30, 2016, by and between Acorda Therapeutics, Inc. and Brenda Vanesse, as amended. • Non-Healthcare Professional Consulting Agreement, dated June 21, 2018, by and between Acorda Therapeutics, Inc. and Brenda Vanesse. 	Brenda Vanesse	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
382.	<ul style="list-style-type: none"> • Consultant Agreement (Non-HCP), dated June 8, 2016, by and between Acorda Therapeutics, Inc. and Steven DeWitte. • Non-Healthcare Professional Consulting Agreement, dated January 16, 2018, by and between Acorda Therapeutics, Inc. and Steven DeWitte. • Non-Healthcare Professional Consulting Agreement, dated August 10, 2018, by and between Acorda Therapeutics, Inc. and Steven DeWitte. 	Steven DeWitte	-
383.	<ul style="list-style-type: none"> • Patient Consultant Agreement (Non-HCP), dated April 4, 2016, by and between Acorda Therapeutics, Inc. and Gary Rafaloff. • Non-Healthcare Professional Consulting Agreement, dated June 21, 2018, by and between Acorda Therapeutics, Inc. and Gary Rafaloff. 	Gary Rafaloff	-
384.	Healthcare Professional Advisory Board Consulting Agreement, dated as of November 13, 2018, by and between Acorda Therapeutics, Inc. and Rajeev Kumar, MD, FRCPC, as amended.	Rajeev Kumar	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
385.	GI Dysfunction in Patients with Parkinson's Disease Video Consulting, dated as of May 13, 2019, by and between Acorda Therapeutics, Inc. and Ronald F. Pfeiffer, MD, as amended.	Ronald Pfeiffer	-